U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H30N4O3
Molecular Weight 422.52
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PNU-142633

SMILES

CNC(=O)C1=CC2=C(C=C1)[C@H](CCN3CCN(CC3)C4=CC=C(C=C4)C(N)=O)OCC2

InChI

InChIKey=PNTVCCRNJOGKGA-QFIPXVFZSA-N
InChI=1S/C24H30N4O3/c1-26-24(30)19-4-7-21-18(16-19)9-15-31-22(21)8-10-27-11-13-28(14-12-27)20-5-2-17(3-6-20)23(25)29/h2-7,16,22H,8-15H2,1H3,(H2,25,29)(H,26,30)/t22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H30N4O3
Molecular Weight 422.52
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

PNU-142633 is selective 5HT1D partial agonist, developed by Pharmacia & Upjohn, Inc. It failed in phase II clinical trials against acute migraine, and its development was discontinued.

Originator

Curator's Comment: Pharmacia was obtained by Pfizer.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
141 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PNU-142633 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg single, oral (unknown)
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
healthy
n = 6
Health Status: healthy
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
Other AEs: Dizziness...
Other AEs:
Dizziness
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness
100 mg single, oral (unknown)
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
healthy
n = 6
Health Status: healthy
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In phase II clinical trials patients received a single 50-mg oral dose of a 5-HT(1D) agonist, PNU-142633 during an acute migraine attack.
Route of Administration: Oral
Receptor binding studies were performed on 5HT1D receptors, expressed in HEK293 cells. Binding of [3H]-serotonin was measured in membranes, using filtration techniques.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:45:45 UTC 2023
Edited
by admin
on Sat Dec 16 10:45:45 UTC 2023
Record UNII
B54P1BQ73L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PNU-142633
Common Name English
1H-2-BENZOPYRAN-6-CARBOXAMIDE, 1-(2-(4-(4-(AMINOCARBONYL)PHENYL)-1-PIPERAZINYL)ETHYL)-3,4-DIHYDRO-N-METHYL-, (1S)-
Systematic Name English
Code System Code Type Description
CAS
187665-65-2
Created by admin on Sat Dec 16 10:45:45 UTC 2023 , Edited by admin on Sat Dec 16 10:45:45 UTC 2023
PRIMARY
EPA CompTox
DTXSID00431734
Created by admin on Sat Dec 16 10:45:45 UTC 2023 , Edited by admin on Sat Dec 16 10:45:45 UTC 2023
PRIMARY
FDA UNII
B54P1BQ73L
Created by admin on Sat Dec 16 10:45:45 UTC 2023 , Edited by admin on Sat Dec 16 10:45:45 UTC 2023
PRIMARY
PUBCHEM
9845148
Created by admin on Sat Dec 16 10:45:45 UTC 2023 , Edited by admin on Sat Dec 16 10:45:45 UTC 2023
PRIMARY
WIKIPEDIA
PNU-142633
Created by admin on Sat Dec 16 10:45:45 UTC 2023 , Edited by admin on Sat Dec 16 10:45:45 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY